Skip to main
BEAM
BEAM logo

Beam Therapeutics (BEAM) Stock Forecast & Price Target

Beam Therapeutics (BEAM) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 25%
Buy 42%
Hold 29%
Sell 4%
Strong Sell 0%

Bulls say

Beam Therapeutics Inc. is actively developing a portfolio of precision genetic medicines utilizing its proprietary base editing technology, focusing on conditions such as Sickle Cell Disease and Alpha-1 antitrypsin deficiency (AATD). Recent Phase 1/2 trial data for BEAM-302 demonstrated a significant increase in corrected M-AAT protein levels beyond 28 days, indicating the potential for durable and lifelong benefits, supported by a favorable lipid nanoparticle formulation that may facilitate outpatient dosing and broader uptake. The company has recently upgraded its platform value, reflecting reduced risks associated with its in-vivo base editing programs, which bolsters the positive outlook for Beam Therapeutics's financial future.

Bears say

Beam Therapeutics Inc faces a negative outlook primarily due to potential payor pushback against its high pricing strategy for one-time genetic treatments, which could significantly diminish its market opportunity in the arena of rare diseases. The reliance on a nascent technology, base editing, poses a risk, as the absence of publicly available clinical datasets means that any setbacks in the pipeline could adversely affect the perception and viability of all its product candidates. Additionally, the company's valuation assumptions, including a 12% discount rate and a zero long-term growth rate, suggest skepticism regarding the sustainability of its business model in light of these challenges.

Beam Therapeutics (BEAM) has been analyzed by 24 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 42% recommend Buy, 29% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beam Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beam Therapeutics (BEAM) Forecast

Analysts have given Beam Therapeutics (BEAM) a Buy based on their latest research and market trends.

According to 24 analysts, Beam Therapeutics (BEAM) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beam Therapeutics (BEAM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.